Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy

Acta Neurologica Scandinavica

Volumn 125, Issue 2, 2012, Pages 129-135

  Zhang, H L ^a,b   Zhang, X M ^a   Mao, X J ^a,c   Deng, H ^b   Li, H F ^d   Press, R ^a   Fredrikson, S ^a   Zhu, J ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d QINGDAO UNIVERSITY   (China)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Fibrinogen; Guillain Barr syndrome; Haptoglobin; Multiple sclerosis; Prealbumin

Indexed keywords

APOLIPOPROTEIN A4; APOLIPOPROTEIN E; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN G; PREALBUMIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; CEREBROSPINAL FLUID PROTEINS; FEMALE; FIBRINOGEN; GUILLAIN-BARRE SYNDROME; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PREALBUMIN;

EID: 84855969624     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01511.x     Document Type: Article

References (22)

1. Brettschneider J, Petzold A, Süssmuth S, Tumani H. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome - Where do we stand? J Neurol 2009;256:3-12.
2. Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 2007;14:563-8.
3. Chang KH, Lyu RK, Tseng MY et al. Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. Proteomics Clin Appl 2007;1:467-75.
4. Yang YR, Liu SL, Qin ZY et al. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Cell Mol Neurobiol 2008;28:737-44.
5. Lehmensiek V, Sussmuth SD, Brettschneider J et al. Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS). J Neuroimmunol 2007;185:190-4.
6. Van Den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004;29:565-74.
7. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:s21-4.
8. Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
9. Van Swieten J, Koudstaal P, Visser M et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
10. Kleyweg RP, Van Der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-9.
11. Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl 1970;44:3-72.
12. Merkies ISJ, Schmitz PIM, Van Der Meché FGA et al. Psychometric evaluation of an overall disability scale in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
13. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-86.
14. Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 2000;1482:65-72.
15. Nunes AF, Saraiva MJ, Sousa MM. Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 2006;20:166-8.
16. Fleming CE, Mar FM, Franquinho F, Sousa MM. Chapter 17: Transthyretin: an enhancer of nerve regeneration. Int Rev Neurobiol 2009;87:337-46.
17. Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 2007;14:2925-36.
18. Levy AP, Asleh R, Blum S et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010;12:293-304.
19. Chiang HL, Lyu RK, Tseng MY et al. Analyses of prealbumin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 2009;405:143-7.
20. Tumani H, Pfeifle M, Lehmensiek V et al. Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid. J Neuroimmunol 2009;214:109-12.
21. Sanjay R, Flanagan J, Sodano D, Gorson KC, Ropper AH, Weinstein R. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome. J Clin Apher 2006;21:105-10.
22. Bai S, Liu S, Guo X et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 2009;15:1638-48.